InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
+0.2%
Across 12 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by LEVIN ALAN G, Director. Insider active across 2 companies, notably Biocryst Pharmaceuticals INC. In total, 16 reports have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €46k. Activity tracked since 31 August 2021. The latest transaction was disclosed on 12 June 2024 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations16 total
15,294 sharesCommon StockSEC:0000882796-26-000052:0
6,820 shares0Common StockSEC:0001127602-24-018725:0
7,861 shares@ US$6.3632.3% of flowCommon StockSEC:0001127602-24-017121:0
Ideal exit: 24 Feb 2025 (T+270)
16,745 shares0Common StockSEC:0001127602-23-018793:0
1,360 shares@ US$8.277.4% of flowCommon StockSEC:0001127602-23-017556:0
1,271 shares@ US$8.857.4% of flowCommon StockSEC:0001127602-23-008381:0
842 shares@ US$13.367.6% of flowCommon StockSEC:0001127602-22-026825:0
809 shares@ US$13.907.8% of flowCommon StockSEC:0001127602-22-022014:0
12,866 shares0Common StockSEC:0001127602-22-017148:0
1,138 shares@ US$9.310.0006% mcap18.5% of flowCommon StockSEC:0001127602-22-016395:0
602 shares@ US$16.610.0005% mcap16.7% of flowCommon StockSEC:0001127602-22-007730:0
829 shares@ US$12.060.0005% mcap16.6% of flowCommon StockSEC:0001127602-21-030059:0
829 shares@ US$12.066.2% of flowCommon StockSEC:0001127602-21-030059
628 shares@ US$15.920.0005% mcap15.8% of flowCommon StockSEC:0001127602-21-024778:0
628 shares@ US$15.925.9% of flowCommon StockSEC:0001127602-21-024778
248,032 sharesCommon StockSEC:0001437749-16-023549:0
16 of 16 declarations
About LEVIN ALAN G
Alan G. Levin is a Board Member at BIOCRYST PHARMACEUTICALS INC. He plays a vital role in the governance of the company, bringing his expertise in biopharmaceuticals and innovation. Levin contributes to formulating strategies that promote growth and sustainable development at BIOCRYST.
